B of A Securities Rates Jazz Pharmaceuticals (JAZZ) buy
A new price target of $307 suggests strong upside for JAZZ shares currently priced at $230.56.
Reviewed by automated data checks against the source data. How we make and check alerts
B of A Securities rated Jazz Pharmaceuticals plc ($JAZZ) "buy" with a $307 price target on June 10, 2026.
Since the rating, $JAZZ is down 1.2% after 1 week, up 6.2% after 1 month and down 8.4% to date (from the $229.63 close on Jun 10, 2026).
JAZZ
Jazz Pharmaceuticals plc
Key Points
- B of A Securities reiterated its Buy rating on JAZZ Pharmaceuticals with a price target of $307 following its recent analysis on June 10, 2026.
- B of A Securities's $307 price target implies 33.15% upside from Jazz Pharmaceuticals plc's ($JAZZ) current $230.56 share price.
- JAZZ shares are trading at $230.56, about 23% lower than the target price, indicating substantial potential for growth.
- The stock has a P/E ratio of 16.5 and is part of the healthcare sector, showing strong fundamentals with a recent revenue of $4.6 billion.
Get $JAZZ trade alerts by text
We text you when insiders, Congress or big funds trade $JAZZ. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Jazz Pharmaceuticals plc alert may contain errors. Disclosures
Analysts Set New Price Targets
On June 10, 2026, B of A Securities reiterated its Buy rating on JAZZ Pharmaceuticals plc (NasdaqGS: JAZZ) with a price target of $307. Analyst Jason Gerberry sees strong potential in the stock, which is currently trading at $230.56.
Stock Price Context
JAZZ shares are currently around $230.56, which is significantly below the target price of $307. This suggests there is potential for growth as the stock trades roughly 23% lower than what analysts expect it could reach. The shares have previously closed at $240.74, indicating recent volatility.
$JAZZ price target
Jazz Pharmaceuticals plc daily closes and this analyst's $307 target. Not advice.
Recent Analyst Opinions
Other analysts have also weighed in on JAZZ. On October 8, 2026, RBC Capital maintained its Outperform rating with a target of $296. Truist Securities also maintained a Buy rating on October 7, adjusting its target to $286. Citigroup initiated coverage with a Buy rating and a target of $325 on September 30, 2026. Overall, the consensus shows a bullish outlook with a mean price target of $290.6 based on 20 analyst opinions.
About JAZZ Pharmaceuticals
JAZZ Pharmaceuticals, based in Dublin, Ireland, develops and markets pharmaceutical products primarily in the U.S. and Europe. The company focuses on areas such as sleep disorders, seizures, and certain cancers, with a variety of products in its portfolio, including Xywav and Epidiolex. JAZZ's strong market presence and product range support its positive outlook from analysts.
What's Ahead for JAZZ
Investors should keep an eye on JAZZ's next earnings report, scheduled for November 4, 2026. This will be an important update for assessing the company’s performance and any changes in analyst sentiment leading up to it. Remember, the B of A Securities report reflects the views as of June 10, 2026, and may not represent the current market situation.
Related Filing Alerts
Source: B of A Securities's rating change on $JAZZ (Jun 10, 2026). Written by software, not financial advice. How we make alerts